{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:26:25Z","timestamp":1791919585643,"version":"4.3.4"},"reference-count":122,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Central nervous system (CNS) diseases are currently a major challenge in medicine. One reason is the presence of the blood\u2013brain barrier, which is a significant limitation for currently used medicinal substances that are characterized by a high molecular weight and a short half-life. Despite the application of nanotechnology, there is still the problem of targeting and the occurrence of systemic toxicity. Viral vectors and virus-like particles (VLPs) may provide a promising solution to these challenges. Their small size, biocompatibility, ability to carry medicinal substances, and specific targeting of neural cells make them useful in research when formulating a new generation of biological carriers. Additionally, the possibility of genetic modification has the potential for gene therapy. Among the most promising viral vectors are adeno-associated viruses, adenoviruses, and retroviruses. This is due to their natural tropism to neural cells, as well as the possibility of genetic and surface modification. Moreover, VLPs that are devoid of infectious genetic material in favor of increasing capacity are also leading the way for research on new drug delivery systems. The aim of this study is to review the most recent reports on the use of viral vectors and VLPs in the treatment of selected CNS diseases.<\/jats:p>","DOI":"10.3390\/pharmaceutics15071931","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:50:41Z","timestamp":1689123041000},"page":"1931","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Virus-Based Biological Systems as Next-Generation Carriers for the Therapy of Central Nervous System Diseases"],"prefix":"10.3390","volume":"15","author":[{"given":"Ilona","family":"Nowak","sequence":"first","affiliation":[{"name":"Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Madej","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Secemska","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sarna","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9854-2569","authenticated-orcid":false,"given":"Barbara","family":"Strzalka-Mrozik","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/med.21764","article-title":"Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions","volume":"41","author":"Vatansever","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s11095-022-03241-x","article-title":"Targeting transporters for drug delivery to the brain: Can we do better?","volume":"39","author":"Puris","year":"2022","journal-title":"Pharm. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.2147\/DDDT.S218708","article-title":"In-vitro blood-brain barrier models for drug screening and permeation studies: An overview","volume":"13","author":"Bagchi","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2017.07.001","article-title":"Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases","volume":"262","author":"Albuquerque","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1801362","DOI":"10.1002\/adma.201801362","article-title":"Overcoming the blood-brain barrier: The role of nanomaterials in treating neurological diseases","volume":"30","author":"Furtado","year":"2018","journal-title":"Adv. Mater."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fneng.2013.00007","article-title":"The blood-brain barrier: An engineering perspective","volume":"6","author":"Wong","year":"2013","journal-title":"Front. Neuroeng."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Blood-brain barrier: From physiology to disease and back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6564585","DOI":"10.1155\/2021\/6564585","article-title":"Blood-brain barrier overview: Structural and functional correlation","volume":"2021","author":"Alahmari","year":"2021","journal-title":"Neural Plast."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41423-021-00757-x","article-title":"The blood-brain barrier in systemic infection and inflammation","volume":"18","author":"Galea","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev-cellbio-100617-062608","article-title":"Development and cell biology of the blood-brain barrier","volume":"35","author":"Langen","year":"2019","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"147937","DOI":"10.1016\/j.brainres.2022.147937","article-title":"Factors influencing the blood-brain barrier permeability","volume":"1788","author":"Zhao","year":"2022","journal-title":"Brain Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Madej, M., Kurowska, N., and Strzalka-Mrozik, B. (2022). Polymeric nanoparticles\u2014Tools in a drug delivery system in selected cancer therapies. Appl. Sci., 12.","DOI":"10.3390\/app12199479"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/164_2020_403","article-title":"Drug delivery strategies to overcome the blood-brain barrier (BBB)","volume":"273","author":"Helms","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Nguyen, T.T., and Maeng, H.J. (2022). Pharmacokinetics and pharmacodynamics of intranasal solid lipid nanoparticles and nanostructured lipid carriers for nose-to-brain delivery. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030572"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Constantinescu, T., Lungu, C.N., and Lung, I. (2019). Lipophilicity as a central component of drug-like properties of chalchones and flavonoid derivatives. Molecules, 24.","DOI":"10.3390\/molecules24081505"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2021.12.030","article-title":"Evolution of drug delivery systems: From 1950 to 2020 and beyond","volume":"342","author":"Park","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2217\/nnm-2018-0139","article-title":"Nanoparticle crossing of blood-brain barrier: A road to new therapeutic approaches to central nervous system diseases","volume":"13","year":"2018","journal-title":"Nanomedicine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jconrel.2021.03.029","article-title":"BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment","volume":"333","author":"Chen","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3389\/fphar.2019.00724","article-title":"Gene therapy tools for brain diseases","volume":"10","author":"Ingusci","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_22","first-page":"763","article-title":"Nanostructured lipid carriers for nose to brain delivery targeting CNS: Diversified role of liquid lipids for synergistic action","volume":"12","author":"Tekade","year":"2022","journal-title":"Adv. Pharm. Bull."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/1061186X.2016.1184272","article-title":"Nano carriers for drug transport across the blood-brain barrier","volume":"25","author":"Li","year":"2017","journal-title":"J. Drug Target."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Afzal, O., Altamimi, A.S.A., Nadeem, M.S., Alzarea, S.I., Almalki, W.H., Tariq, A., Mubeen, B., Murtaza, B.N., Iftikhar, S., and Riaz, N. (2022). Nanoparticles in drug delivery: From history to therapeutic applications. Nanomaterials, 12.","DOI":"10.3390\/nano12244494"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Xie, J., Shen, Z., Anraku, Y., Kataoka, K., and Chen, X. (2019). Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials, 224.","DOI":"10.1016\/j.biomaterials.2019.119491"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Turek, A., Rech, J., Borecka, A., Wili\u0144ska, J., Kobielarz, M., Janeczek, H., and Kasperczyk, J. (2021). The role of the mechanical, structural, and thermal properties of poly(l-lactide-co-glycolide-co-trimethylene carbonate) in the development of rods with aripiprazole. Polymers, 13.","DOI":"10.3390\/polym13203556"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.32725\/jab.2022.010","article-title":"Effects of 17-\u03b2-estradiol released from shape-memory terpolymer rods on sciatic nerve regeneration after injury and repair with chitosan nerve conduit in female rats","volume":"20","author":"Olakowska","year":"2022","journal-title":"J. Appl. Biomed."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"113642","DOI":"10.1016\/j.jpba.2020.113642","article-title":"Analytical characterization of liposomes and other lipid nanoparticles for drug delivery","volume":"192","author":"Fan","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mittal, P., Saharan, A., Verma, R., Altalbawy, F.M.A., Alfaidi, M.A., Batiha, G.E., Akter, W., Gautam, R.K., Uddin, M.S., and Rahman, M.S. (2021). Dendrimers: A new race of pharmaceutical nanocarriers. Biomed. Res. Int., 2021.","DOI":"10.1155\/2021\/8844030"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s41061-019-0278-8","article-title":"Carbon nanotubes in biomedicine","volume":"378","author":"Negri","year":"2020","journal-title":"Top Curr. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.2174\/1567205014666170508121031","article-title":"Nanotechnology based theranostic approaches in Alzheimer\u2019s disease management: Current status and future perspective","volume":"14","author":"Ahmad","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1695","DOI":"10.1002\/wnan.1695","article-title":"Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases","volume":"13","author":"Zhou","year":"2021","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Butt, M.H., Zaman, M., Ahmad, A., Khan, R., Mallhi, T.H., Hasan, M.M., Khan, Y.H., Hafeez, S., Massoud, E.E.S., and Rahman, M.H. (2022). Appraisal for the potential of viral and nonviral vectors in gene therapy: A review. Genes, 13.","DOI":"10.3390\/genes13081370"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"114102","DOI":"10.1016\/j.expneurol.2022.114102","article-title":"The use of viral vectors to promote repair after spinal cord injury","volume":"354","author":"Islam","year":"2022","journal-title":"Exp. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00262-021-02856-0","article-title":"Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma","volume":"70","author":"Huang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.gene.2016.04.032","article-title":"Transfer of three transcription factors via a lentiviral vector ameliorates spatial learning and memory impairment in a mouse model of Alzheimer\u2019s disease","volume":"587","author":"Chen","year":"2016","journal-title":"Gene"},{"key":"ref_37","first-page":"1508","article-title":"Systemic AAV9-IFN\u03b2 gene delivery treats highly invasive glioblastoma","volume":"18","author":"GuhaSarkar","year":"2016","journal-title":"Neuro-oncology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1038\/emm.2017.302","article-title":"Intrahippocampal injection of a lentiviral vector expressing neurogranin enhances cognitive function in 5XFAD mice","volume":"50","author":"Jeon","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7785\/tcrt.2012.500362","article-title":"Lentiviral vector mediated delivery of RHBDD1 shRNA down regulated the proliferation of human glioblastoma cells","volume":"13","author":"Wei","year":"2014","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s13311-018-0650-3","article-title":"A dendritic cell-targeted adenoviral vector facilitates adaptive immune response against human glioma antigen (CMV-IE) and prolongs survival in a human glioma tumor model","volume":"15","author":"Kim","year":"2018","journal-title":"Neurotherapeutics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-9966-31-8","article-title":"Adenovirus-mediated delivery of CALR and MAGE-A3 inhibits invasion and angiogenesis of glioblastoma cell line U87","volume":"31","author":"Liu","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1080\/10717544.2022.2035855","article-title":"Microbubble drug conjugate and focused ultrasound blood brain barrier delivery of AAV-2 SIRT-3","volume":"29","author":"Trinh","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/humc.2017.231","article-title":"AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer\u2019s disease","volume":"29","author":"Rosenberg","year":"2018","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12974-022-02382-5","article-title":"TRPV4 contributes to ER stress and inflammation: Implications for Parkinson\u2019s disease","volume":"19","author":"Liu","year":"2022","journal-title":"J. Neuroinflamm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1111\/bph.12662","article-title":"Using viruses as nanomedicines","volume":"171","author":"Cornelissen","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/wnan.1287","article-title":"Synthetic virology: Engineering viruses for gene delivery","volume":"6","author":"Guenther","year":"2014","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejps.2012.02.022","article-title":"Conjugation of paclitaxel on adeno-associated virus (AAV) nanoparticles for co-delivery of genes and drugs","volume":"46","author":"Wei","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9493","DOI":"10.1002\/anie.200902426","article-title":"Genome-free viral capsids as multivalent carriers for taxol delivery","volume":"48","author":"Wu","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1021\/acschembio.6b00060","article-title":"Chemically modifying viruses for diverse applications","volume":"11","author":"Mohan","year":"2016","journal-title":"ACS. Chem. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"El Andari, J., and Grimm, D. (2021). Production, processing, and characterization of synthetic AAV gene therapy vectors. Biotechnol. J., 16.","DOI":"10.1002\/biot.202000025"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Duverg\u00e9, A., and Negroni, M. (2020). Pseudotyping lentiviral vectors: When the clothes make the virus. Viruses, 12.","DOI":"10.3390\/v12111311"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00109-022-02208-0","article-title":"Adenoviral vectors for cardiovascular gene therapy applications: A clinical and industry perspective","volume":"100","author":"Schwartze","year":"2022","journal-title":"J. Mol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Labb\u00e9, R.P., Vessillier, S., and Rafiq, Q.A. (2021). Lentiviral vectors for T cell engineering: Clinical applications, bioprocessing and future perspectives. Viruses, 13.","DOI":"10.3390\/v13081528"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41392-021-00631-2","article-title":"Recent progress in targeted delivery vectors based on biomimetic nanoparticles","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fnmol.2020.00129","article-title":"Intramuscular delivery of gene therapy for targeting the nervous system","volume":"13","author":"Tosolini","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.2174\/1570159X18666200528142429","article-title":"Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer\u2019s disease","volume":"18","author":"Khan","year":"2020","journal-title":"Curr. Neuropharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Breijyeh, Z., and Karaman, R. (2020). Comprehensive review on Alzheimer\u2019s disease: Causes and treatment. Molecules, 25.","DOI":"10.3390\/molecules25245789"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.2147\/IJN.S200490","article-title":"Alzheimer\u2019s disease: Pathogenesis, diagnostics, and therapeutics","volume":"14","author":"Tiwari","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"F1000 Faculty Rev-1161","DOI":"10.12688\/f1000research.14506.1","article-title":"Current understanding of Alzheimer\u2019s disease diagnosis and treatment","volume":"7","author":"Weller","year":"2018","journal-title":"F1000Research"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"931","DOI":"10.4103\/1673-5374.250570","article-title":"Characteristics and advantages of adeno-associated virus vector-mediated gene therapy for neurodegenerative diseases","volume":"14","author":"Qu","year":"2019","journal-title":"Neural Regen. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12035-018-1068-y","article-title":"Targeted gene editing of glia maturation factor in microglia: A novel Alzheimer\u2019s disease therapeutic target","volume":"56","author":"Raikwar","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/02648725.2018.1523521","article-title":"Current viral-mediated gene transfer research for treatment of Alzheimer\u2019s disease","volume":"35","author":"Sasmita","year":"2019","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.4103\/1673-5374.237108","article-title":"Neuroprotection by immunomodulatory agents in animal models of Parkinson\u2019s disease","volume":"13","author":"Martinez","year":"2018","journal-title":"Neural Regen. Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Church, F.C. (2021). Treatment options for motor and non-motor symptoms of Parkinson\u2019s disease. Biomolecules, 11.","DOI":"10.3390\/biom11040612"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"113049","DOI":"10.1016\/j.yexcr.2022.113049","article-title":"Neurturin promotes tumor cell motility and angiogenesis in colorectal cancer","volume":"413","author":"Wang","year":"2022","journal-title":"Exp. Cell Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1038\/s41467-021-24524-8","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons","volume":"12","author":"Pearson","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: A review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"53","DOI":"10.7861\/clinmedicine.16-6-s53","article-title":"Multiple sclerosis, a treatable disease","volume":"16","author":"Doshi","year":"2016","journal-title":"Clin. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.omtm.2022.04.011","article-title":"Treatment of experimental autoimmune encephalomyelitis using AAV gene therapy by blocking T cell costimulatory pathways","volume":"25","author":"Zhong","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ymthe.2017.09.001","article-title":"Gene therapy-induced antigen-specific Tregs inhibit neuro-inflammation and reverse disease in a mouse model of multiple sclerosis","volume":"26","author":"Keeler","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4049\/jimmunol.1801462","article-title":"Treatment of experimental autoimmune encephalomyelitis by sustained delivery of low-dose IFN-\u03b1","volume":"203","author":"Vasquez","year":"2019","journal-title":"J. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"105084","DOI":"10.1016\/j.micinf.2022.105084","article-title":"Is there a role for herpes simplex virus type 1 in multiple sclerosis?","volume":"25","author":"Duarte","year":"2022","journal-title":"Microbes Infect."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"105780","DOI":"10.1016\/j.phrs.2021.105780","article-title":"Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance","volume":"171","author":"Wu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.neuroscience.2022.03.030","article-title":"Recent advances in the therapeutic strategies of glioblastoma multiforme","volume":"491","author":"Aldoghachi","year":"2022","journal-title":"Neuroscience"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11060-020-03499-4","article-title":"Surgical strategy for insular glioma","volume":"151","author":"Przybylowski","year":"2021","journal-title":"J. Neurooncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.3390\/curroncol30020147","article-title":"Temozolomide chronotherapy in glioma: A systematic review","volume":"30","author":"Jia","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Kushiya, H., Hiraoka, K., Suzuki, T., Inoko, K., Inagaki, A., Niwa, H., Sasaki, K., Nakamura, T., Tsuchikawa, T., and Shichinohe, T. (2022). Retroviral replicating vector Toca 511 (vocimagene amiretrorepvec) for prodrug activator gene therapy of lung cancer. Cancers, 14.","DOI":"10.20944\/preprints202207.0015.v1"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/14712598.2021.1902982","article-title":"Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer","volume":"21","author":"Collins","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Rech, J., Getinger-Panek, A., Ga\u0142ka, S., and Bednarek, I. (2022). Origin and composition of exosomes as crucial factors in designing drug delivery systems. Appl. Sci., 12.","DOI":"10.3390\/app122312259"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"8596","DOI":"10.1021\/acs.jmedchem.1c01946","article-title":"Glioblastoma: Current status, emerging targets, and recent advances","volume":"65","author":"Thakur","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/13543784.2019.1572112","article-title":"Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma","volume":"28","author":"Philbrick","year":"2019","journal-title":"Expert Opin. Investig. Drugs."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1061257","DOI":"10.3389\/fnmol.2022.1061257","article-title":"Dual-function AAV gene therapy reverses late-stage Canavan disease pathology in mice","volume":"15","author":"Kalotay","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1089\/104303402760128612","article-title":"Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain","volume":"13","author":"Janson","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"695937","DOI":"10.3389\/fnmol.2021.695937","article-title":"Current and future prospects for gene therapy for rare genetic diseases affecting the brain and spinal cord","volume":"14","author":"Jensen","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-0-12-800149-3.00002-0","article-title":"Clinical applications involving CNS gene transfer","volume":"87","author":"Kantor","year":"2014","journal-title":"Adv. Genet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"104391","DOI":"10.1016\/j.isci.2022.104391","article-title":"Therapeutic development for Canavan disease using patient iPSCs introduced with the wild-type ASPA gene","volume":"25","author":"Chao","year":"2022","journal-title":"iScience"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/978-1-4939-3271-9_30","article-title":"Gene therapy for the treatment of neurological disorders: Metabolic disorders","volume":"1382","author":"Gessler","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"165ra163","DOI":"10.1126\/scitranslmed.3003454","article-title":"Long-term follow-up after gene therapy for canavan disease","volume":"4","author":"Leone","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/mt.2013.138","article-title":"A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice","volume":"21","author":"Ahmed","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2002155","DOI":"10.1002\/advs.202002155","article-title":"Cell-based therapy for Canavan disease using human iPSC-derived NPCs and OPCs","volume":"7","author":"Feng","year":"2020","journal-title":"Adv. Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e2201583","DOI":"10.1002\/adhm.202201583","article-title":"Genetically engineered viral vectors and organic-based non-viral nanocarriers for drug delivery applications","volume":"11","author":"Hajebi","year":"2022","journal-title":"Adv. Healthc. Mater."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Nguyen, T.T., Dung Nguyen, T.T., Vo, T.K., Tran, N.M., Nguyen, M.K., Van Vo, T., and Van Vo, G. (2021). Nanotechnology-based drug delivery for central nervous system disorders. Biomed. Pharmacother., 143.","DOI":"10.1016\/j.biopha.2021.112117"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1515\/tnsci-2022-0258","article-title":"Nanotechnology-based drug delivery for the treatment of CNS disorders","volume":"13","author":"Mittal","year":"2022","journal-title":"Transl. Neurosci."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Mej\u00eda-M\u00e9ndez, J.L., Vazquez-Duhalt, R., Hern\u00e1ndez, L.R., S\u00e1nchez-Arreola, E., and Bach, H. (2022). Virus-like particles: Fundamentals and biomedical applications. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158579"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"975054","DOI":"10.3389\/fmolb.2022.975054","article-title":"Quality assessment of virus-like particle: A new transmission electron microscopy approach","volume":"9","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"He, J., Yu, L., Lin, X., Liu, X., Zhang, Y., Yang, F., and Deng, W. (2022). Virus-like particles as nanocarriers for intracellular delivery of biomolecules and compounds. Viruses, 14.","DOI":"10.3390\/v14091905"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12981-020-00293-0","article-title":"JC Polyomavirus, progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome: A review","volume":"17","author":"Harypursat","year":"2020","journal-title":"AIDS Res. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3389\/fimmu.2020.01100","article-title":"Interaction between virus-like particles (VLPs) and pattern recognition receptors (PRRs) from dendritic cells (DCs): Toward better engineering of VLPs","volume":"11","author":"Vaca","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Finbloom, J.A., Aanei, I.L., Bernard, J.M., Klass, S.H., Elledge, S.K., Han, K., Ozawa, T., Nicolaides, T.P., Berger, M.S., and Francis, M.B. (2018). Evaluation of three morphologically distinct virus-like particles as nanocarriers for convection-enhanced drug delivery to glioblastoma. Nanomaterials, 8.","DOI":"10.3390\/nano8121007"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Yang, Z., Chi, Y., Bao, J., Zhao, X., Zhang, J., and Wang, L. (2022). Virus-like particles for TEM regulation and antitumor therapy. J. Funct. Biomater., 13.","DOI":"10.3390\/jfb13040304"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.omtm.2022.12.003","article-title":"Stimulation of the immune system by a tumor antigen-bearing adenovirus-inspired VLP allows control of melanoma growth","volume":"28","author":"Besson","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nbt.2017.07.010","article-title":"Production of virus-like particles for vaccines","volume":"39","author":"Fuenmayor","year":"2017","journal-title":"N. Biotechnol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"790121","DOI":"10.3389\/fmicb.2021.790121","article-title":"Virus-like particles: Revolutionary platforms for developing vaccines against emerging infectious diseases","volume":"12","author":"Tariq","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"102785","DOI":"10.1016\/j.copbio.2022.102785","article-title":"Virus-like particles for drug delivery: A review of methods and applications","volume":"78","author":"Ikwuagwu","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1123805","DOI":"10.3389\/fimmu.2023.1123805","article-title":"Platforms, advances, and technical challenges in virus-like particles-based vaccines","volume":"14","author":"Gupta","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"16579","DOI":"10.1038\/s41598-021-95891-x","article-title":"Chimeric virus-like particles (VLPs) designed from shrimp nodavirus (MrNV) capsid protein specifically target EGFR-positive human colorectal cancer cells","volume":"11","author":"Grataitong","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Tornesello, A.L., Tagliamonte, M., Buonaguro, F.M., Tornesello, M.L., and Buonaguro, L. (2022). Virus-like particles as preventive and therapeutic cancer vaccines. Vaccines, 10.","DOI":"10.3390\/vaccines10020227"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12257-022-0107-8","article-title":"Virus-like particles as antiviral vaccine: Mechanism, design, and application","volume":"6","author":"Zhang","year":"2023","journal-title":"Biotechnol. Bioprocess Eng."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"FSO744","DOI":"10.2144\/fsoa-2021-0031","article-title":"The viral capsid as novel nanomaterials for drug delivery","volume":"7","author":"Aljabali","year":"2021","journal-title":"Future Sci. OA"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13195-018-0378-7","article-title":"Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer\u2019s disease and frontotemporal dementia","volume":"10","author":"Ji","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-019-0118-4","article-title":"Q\u00df virus-like particle-based vaccine induces robust immunity and protects against tauopathy","volume":"4","author":"Maphis","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s10787-017-0408-2","article-title":"Plant-based chimeric HPV-virus-like particles bearing amyloid-\u03b2 epitopes elicit antibodies able to recognize amyloid plaques in APP-tg mouse and Alzheimer\u2019s disease brains","volume":"26","author":"Gevorkian","year":"2018","journal-title":"Inflammopharmacology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41541-017-0030-8","article-title":"Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer\u2019s and cat allergy","volume":"2","author":"Zeltins","year":"2017","journal-title":"NPJ Vaccines"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Daddacha, W., Monroe, D., Carver, K., Usoro, E.R., Alptekin, A., Xu, H., Osuka, S., Arbab, A.S., and Sakamuro, D. (2022). Viral particle-mediated SAMHD1 depletion sensitizes refractory glioblastoma to DNA-damaging therapeutics by impairing homologous recombination. Cancers, 14.","DOI":"10.3390\/cancers14184490"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1038\/s41598-018-19825-w","article-title":"Gene therapy for human glioblastoma using neurotropic JC virus-like particles as a gene delivery vector","volume":"8","author":"Chao","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.1039\/C9NR01247H","article-title":"Bioengineering fluorescent virus-like particle\/RNAi nanocomplexes act synergistically with temozolomide to eradicate brain tumors","volume":"11","author":"Pang","year":"2019","journal-title":"Nanoscale"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/acs.molpharmaceut.0c01053","article-title":"Bluetongue virus particles as nanoreactors for enzyme delivery and cancer therapy","volume":"18","author":"Thuenemann","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2217\/nnm-2020-0066","article-title":"Nanoparticle-based co-delivery of siRNA and paclitaxel for dual-targeting of glioblastoma","volume":"15","author":"Yang","year":"2020","journal-title":"Nanomedicine"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Doucet, M., El-Turabi, A., Zabel, F., Hunn, B.H.M., Bengoa-Vergniory, N., Cioroch, M., Ramm, M., Smith, A.M., Gomes, A.C., and Cabral de Miranda, G. (2017). Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181844"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14760584.2022.2072302","article-title":"Quantification methods for viruses and virus-like particles applied in biopharmaceutical production processes","volume":"21","author":"Lothert","year":"2022","journal-title":"Expert Rev. Vaccines"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/7\/1931\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:10:46Z","timestamp":1760127046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/7\/1931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":122,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["pharmaceutics15071931"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15071931","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]}}}